Key result
Beta-blocker therapy reduced one-year all-cause mortality by 24% compared to placebo in post-infarction patients, with high-risk subgroups deriving the greatest benefit.
Why the study?
Does beta-blocker therapy reduce one-year all-cause mortality in post-infarction patients?
Population
13,679 post-infarction patients from 9 major long-term secondary prevention trials
Comparison
Beta-blocker therapy vs Placebo
Design
Meta-analysis
Follow-up
One year
Loading...
Supports beta-blocker use post-MI; confirms mortality benefit and prioritizes high-risk subgroups.
Meta-Analysis (n=13,679)
Yes
Does beta-blocker therapy reduce one-year all-cause mortality in post-infarction patients?
Effect estimate: 24% reduction
Beta-blocker therapy reduces one-year all-cause mortality by 24% in post-infarction patients, with the greatest absolute benefit seen in high-risk subgroups.
A 1988 study conducted a meta-analysis in Post-myocardial infarction (n=13,679). Beta-blocker therapy vs. Placebo was evaluated on One-year all-cause mortality (24% reduction). Beta-blocker therapy reduced one-year all-cause mortality by 24% compared to placebo in post-infarction patients, with high-risk subgroups deriving the greatest benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: